Search
HZT-501
go.drugbank.com/drugs/DB05369InvestigationalHZT-501 is under investigation by Horizon Therapeutics, Inc., a privately held biopharmaceutical company.
QR-334
go.drugbank.com/drugs/DB05473ExperimentalSialorrhea is an excess secretion of saliva produced by the salivary glands, resulting in drooling. No pharmaceutical interventions currently exist to treat sialorrhea.
Alaproclate
go.drugbank.com/drugs/DB13233ExperimentalAlaproclate was developed as one of the first selective serotonin reuptake inhibitor (SSRI) antidepressants by Astra AB (now AstraZeneca) in the 1970s.
Penimepicycline
go.drugbank.com/drugs/DB13264ExperimentalIt is mentioned on List A produced by the Government of Canada, which is a list of antimicrobial active pharmaceutical ingredients [L2791].
Firocoxib
go.drugbank.com/drugs/DB09217ExperimentalVet approvedFirocoxib was the first COX-2 inhibitor approved by the U.S. Food and Drug Administration for horses. Firocoxib is not intended or approved for use in human medicine.
Azelnidipine
go.drugbank.com/drugs/DB09230InvestigationalIt is marketed by Daiichi-Sankyo pharmaceuticals, Inc. in Japan.
Fimasartan
go.drugbank.com/drugs/DB09279InvestigationalFimasartan was initially approved September 9th, 2010 in South Korea and is marketed under the brand name _Kanarb_ by Boryung Pharmaceuticals.
Anti-SARS-CoV-2 IgY
go.drugbank.com/drugs/DB16356InvestigationalFrom there, the chicken antibodies are harvested from the egg yolks of the eggs laid by these chickens and formulated into the nasal drops that can be administered. … [L27381] To create these antibodies, chickens are injected in the chest with the spike protein, which is the surface protein of SARS-CoV-2; this results in an immune response mounted by the chickens towards
Indopan
go.drugbank.com/drugs/DB01446ExperimentalIllicitIt was developed in the 1960's by Upjohn with the intention for use as an antidepressant. In the 1990's, indopan became regulated as a Schedule I controlled substance in the United states.
ATX-201
go.drugbank.com/drugs/DB05765InvestigationalIt is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis.